BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Teixidó J, Martínez-Moreno M, Díaz-Martínez M, Sevilla-Movilla S. The good and bad faces of the CXCR4 chemokine receptor. Int J Biochem Cell Biol 2018;95:121-31. [PMID: 29288743 DOI: 10.1016/j.biocel.2017.12.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Leo M, Sabatino L. Targeting CXCR4 and CD47 Receptors: An Overview of New and Old Molecules for a Biological Personalized Anticancer Therapy. IJMS 2022;23:12499. [DOI: 10.3390/ijms232012499] [Reference Citation Analysis]
2 Santana DS, Silva MJA, de Marin ABR, Costa VLDS, Sousa GSM, de Sousa JG, Silva DC, da Cruz EC, Lima LNGC. The influence Between C-C Chemokine Receptor 5 (CCR5) Genetic Polymorphisms and the Type-1 Human Immunodeficiency Virus (HIV-1): a 20 years review. AIDS Res Hum Retroviruses 2022. [PMID: 36226448 DOI: 10.1089/AID.2022.0111] [Reference Citation Analysis]
3 Zhao R, Liu J, Li Z, Zhang W, Wang F, Zhang B. Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy. Pharmaceutics 2022;14:1541. [PMID: 35893797 DOI: 10.3390/pharmaceutics14081541] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ha DTT, Glab-Ampai K, Rojsitthisak P, Vajragupta O. Production of human embryonic kidney 293T cells stably expressing C-X-C chemokine receptor type 4 (CXCR4) as a screening tool for anticancer lead compound targeting CXCR4. Life Sci 2022;303:120661. [PMID: 35643380 DOI: 10.1016/j.lfs.2022.120661] [Reference Citation Analysis]
5 Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, Adebayo O, Bash H, Chen Y, Maksimos M, Muz B, Azab AK. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. J Immunother Cancer 2022;10:e003975. [DOI: 10.1136/jitc-2021-003975] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
6 Goïta AA, Guenot D. Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7. Cancers 2022;14:1810. [DOI: 10.3390/cancers14071810] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Li Q, Wang M, Zeng L, Guo W, Xu Y, Li C, Lai Y, Ye L, Peng X. Deletion of Wild-type p53 Facilitates Bone Metastatic Function by Blocking the AIP4 Mediated Ligand-Induced Degradation of CXCR4. Front Pharmacol 2021;12:792293. [PMID: 35177982 DOI: 10.3389/fphar.2021.792293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhu Z, Zhang G, Li D, Yin X, Wang T. Silencing of specificity protein 1 protects H9c2 cells against lipopolysaccharide-induced injury via binding to the promoter of chemokine CXC receptor 4 and suppressing NF-κB signaling. Bioengineered 2022;13:3395-409. [PMID: 35048778 DOI: 10.1080/21655979.2022.2026548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nugraha AP, Kitaura H, Ohori F, Pramusita A, Ogawa S, Noguchi T, Marahleh A, Nara Y, Kinjo R, Mizoguchi I. C‑X‑C receptor 7 agonist acts as a C‑X‑C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption. Mol Med Rep 2022;25:78. [PMID: 35014674 DOI: 10.3892/mmr.2022.12594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chatterjee M. Atypical Roles of the Chemokine Receptor ACKR3/CXCR7 in Platelet Pathophysiology. Cells 2022;11:213. [PMID: 35053329 DOI: 10.3390/cells11020213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Satsu H, Fukumura M, Watari K. Regulation of CXCR4 Expression by Taurine in Macrophage-Like Cells. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-030-93337-1_4] [Reference Citation Analysis]
12 Siwicka-Gieroba D, Dabrowski W. Credibility of the Neutrophil-to-Lymphocyte Count Ratio in Severe Traumatic Brain Injury. Life (Basel) 2021;11:1352. [PMID: 34947883 DOI: 10.3390/life11121352] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Kwon SH, Na JI, Huh CH, Park KC. A Clinical and Biochemical Evaluation of a Temperature-Controlled Continuous Non-Invasive Radiofrequency Device for the Treatment of Melasma. Ann Dermatol 2021;33:522-30. [PMID: 34858003 DOI: 10.5021/ad.2021.33.6.522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Aspnes GE, Menhaji-Klotz E, Boehm M, Londregan AT, Lee ECY, Limberakis C, Coffey SB, Brown JA, Jones RM, Hesp KD. Discovery and evaluation of non-basic small molecule modulators of the atypical chemokine receptor CXCR7. Bioorg Med Chem Lett 2021;50:128320. [PMID: 34400299 DOI: 10.1016/j.bmcl.2021.128320] [Reference Citation Analysis]
15 Floranović MP, Petrović AR, Veličković LJ. Expression of the CXCR4 and CXCR7 in renal cancers; can "the orphan receptor" predict the mortality? Ann Diagn Pathol 2021;55:151829. [PMID: 34563828 DOI: 10.1016/j.anndiagpath.2021.151829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang S, Gao S, Li Y, Qian X, Luan J, Lv X. Emerging Importance of Chemokine Receptor CXCR4 and Its Ligand in Liver Disease. Front Cell Dev Biol 2021;9:716842. [PMID: 34386499 DOI: 10.3389/fcell.2021.716842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Britton C, Poznansky MC, Reeves P. Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune-mediated diseases. FASEB J 2021;35:e21260. [PMID: 33715207 DOI: 10.1096/fj.202001273R] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
18 Yan Y, Xiong J, Xu F, Wang C, Zeng Z, Tang H, Lu Z, Huang Q. SDF-1α/CXCR4 Pathway Mediates Hemodynamics-Induced Formation of Intracranial Aneurysm by Modulating the Phenotypic Transformation of Vascular Smooth Muscle Cells. Transl Stroke Res 2021. [PMID: 34173205 DOI: 10.1007/s12975-021-00925-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Ghafouri-Fard S, Dinger ME, Maleki P, Taheri M, Hajiesmaeili M. Emerging role of circular RNAs in the pathobiology of lung cancer. Biomed Pharmacother 2021;141:111805. [PMID: 34120067 DOI: 10.1016/j.biopha.2021.111805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Potić Floranović M, Ristić Petrović A, Veličković F, Janković Veličković L. Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma. Clin Exp Nephrol 2021;25:1057-69. [PMID: 34109508 DOI: 10.1007/s10157-021-02081-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Armani-Tourret M, Zhou Z, Gasser R, Staropoli I, Cantaloube-Ferrieu V, Benureau Y, Garcia-Perez J, Pérez-Olmeda M, Lorin V, Puissant-Lubrano B, Assoumou L, Delaugerre C, Lelièvre JD, Lévy Y, Mouquet H, Martin-Blondel G, Alcami J, Arenzana-Seisdedos F, Izopet J, Colin P, Lagane B. Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis. PLoS Pathog 2021;17:e1009526. [PMID: 33872329 DOI: 10.1371/journal.ppat.1009526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Weich A, Rogoll D, Gawlas S, Mayer L, Weich W, Pongracz J, Kudlich T, Meining A, Scheurlen M. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [68Ga] Pentixafor Internalization in Neuroendocrine Tumor Cells. Diagnostics (Basel) 2021;11:367. [PMID: 33671498 DOI: 10.3390/diagnostics11020367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Senf K, Karius J, Stumm R, Neuhaus EM. Chemokine signaling is required for homeostatic and injury-induced neurogenesis in the olfactory epithelium. Stem Cells 2021;39:617-35. [PMID: 33470495 DOI: 10.1002/stem.3338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li L, Chai Y, Wu C, Zhao L. Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies. Expert Rev Hematol 2020;13:1387-96. [PMID: 33170753 DOI: 10.1080/17474086.2020.1839885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Luker GD, Yang J, Richmond A, Scala S, Festuccia C, Schottelius M, Wester HJ, Zimmermann J. At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. J Leukoc Biol 2021;109:969-89. [PMID: 33104270 DOI: 10.1002/JLB.2BT1018-715RR] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
26 Liang Z, Huang D, Zhang M, Yi X, Wu F, Zhu D, Ning Y, Gan H, Li H. [In vitro study on promoting migration ability of rat adipose derived stem cells modified by stromal cell-derived factor 1α]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2020;34:1305-12. [PMID: 33063498 DOI: 10.7507/1002-1892.202004134] [Reference Citation Analysis]
27 Milanesi S, Locati M, Borroni EM. Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia. Int J Mol Sci 2020;21:E5696. [PMID: 32784523 DOI: 10.3390/ijms21165696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
28 Mierzejewski B, Grabowska I, Jackowski D, Irhashava A, Michalska Z, Stremińska W, Jańczyk-Ilach K, Ciemerych MA, Brzoska E. Mouse CD146+ muscle interstitial progenitor cells differ from satellite cells and present myogenic potential. Stem Cell Res Ther 2020;11:341. [PMID: 32762770 DOI: 10.1186/s13287-020-01827-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Negri S, Faris P, Rosti V, Antognazza MR, Lodola F, Moccia F. Endothelial TRPV1 as an Emerging Molecular Target to Promote Therapeutic Angiogenesis. Cells 2020;9:E1341. [PMID: 32471282 DOI: 10.3390/cells9061341] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
30 Korbecki J, Simińska D, Kojder K, Grochans S, Gutowska I, Chlubek D, Baranowska-Bosiacka I. Fractalkine/CX3CL1 in Neoplastic Processes. Int J Mol Sci 2020;21:E3723. [PMID: 32466280 DOI: 10.3390/ijms21103723] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
31 Kallergi G, Hoffmann O, Bittner AK, Papadimitriou L, Katsarou SD, Zacharopoulou N, Zervakis M, Sfakianakis S, Stournaras C, Georgoulias V, Kimmig R, Kasimir-Bauer S. CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. Ther Adv Med Oncol 2020;12:1758835919895754. [PMID: 32426042 DOI: 10.1177/1758835919895754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Scala S, D'Alterio C, Milanesi S, Castagna A, Carriero R, Farina FM, Locati M, Borroni EM. New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM. Vaccines (Basel) 2020;8:E164. [PMID: 32260318 DOI: 10.3390/vaccines8020164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Németh T, Sperandio M, Mócsai A. Neutrophils as emerging therapeutic targets. Nat Rev Drug Discov 2020;19:253-75. [DOI: 10.1038/s41573-019-0054-z] [Cited by in Crossref: 233] [Cited by in F6Publishing: 243] [Article Influence: 116.5] [Reference Citation Analysis]
34 Renard I, Archibald SJ. CXCR4-targeted metal complexes for molecular imaging. Medicinal Chemistry 2020. [DOI: 10.1016/bs.adioch.2019.11.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Mu W, Wang Z, Zöller M. Ping-Pong-Tumor and Host in Pancreatic Cancer Progression. Front Oncol 2019;9:1359. [PMID: 31921628 DOI: 10.3389/fonc.2019.01359] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
36 Floranović MP, Veličković LJ. Effect of CXCL12 and Its Receptors on Unpredictable Renal Cell Carcinoma. Clin Genitourin Cancer 2020;18:e337-42. [PMID: 31882334 DOI: 10.1016/j.clgc.2019.11.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
37 Nguyen KTP, Druhan LJ, Avalos BR, Zhai L, Rauova L, Nesmelova IV, Dréau D. CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration. Cell Signal 2020;66:109488. [PMID: 31785332 DOI: 10.1016/j.cellsig.2019.109488] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Kowalski K, Brzoska E, Ciemerych MA. The role of CXC receptors signaling in early stages of mouse embryonic stem cell differentiation. Stem Cell Res 2019;41:101636. [PMID: 31722287 DOI: 10.1016/j.scr.2019.101636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Sun Z, Li X, Zheng X, Cao P, Yu B, Wang W. Stromal cell-derived factor-1/CXC chemokine receptor 4 axis in injury repair and renal transplantation. J Int Med Res 2019;47:5426-40. [PMID: 31581874 DOI: 10.1177/0300060519876138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Adlere I, Caspar B, Arimont M, Dekkers S, Visser K, Stuijt J, de Graaf C, Stocks M, Kellam B, Briddon S, Wijtmans M, de Esch I, Hill S, Leurs R. Modulators of CXCR4 and CXCR7/ACKR3 Function. Mol Pharmacol 2019;96:737-52. [DOI: 10.1124/mol.119.117663] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
41 Bobkov V, Arimont M, Zarca A, De Groof TWM, van der Woning B, de Haard H, Smit MJ. Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3. Mol Pharmacol 2019;96:753-64. [PMID: 31481460 DOI: 10.1124/mol.119.116954] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
42 Kallergi G, Tsintari V, Sfakianakis S, Bei E, Lagoudaki E, Koutsopoulos A, Zacharopoulou N, Alkahtani S, Alarifi S, Stournaras C, Zervakis M, Georgoulias V. The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization. Breast Cancer Res 2019;21:86. [PMID: 31370904 DOI: 10.1186/s13058-019-1166-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
43 Jafarzadeh A, Nemati M, Jafarzadeh S. The important role played by chemokines influence the clinical outcome of Helicobacter pylori infection. Life Sci 2019;231:116688. [PMID: 31348950 DOI: 10.1016/j.lfs.2019.116688] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
44 Ullah TR. The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond. J Bone Oncol 2019;17:100253. [PMID: 31372333 DOI: 10.1016/j.jbo.2019.100253] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
45 Righetti A, Giulietti M, Šabanović B, Occhipinti G, Principato G, Piva F. CXCL12 and Its Isoforms: Different Roles in Pancreatic Cancer? J Oncol 2019;2019:9681698. [PMID: 31275385 DOI: 10.1155/2019/9681698] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
46 Floss DM, Scheller J. Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy. Cytokine Growth Factor Rev 2019;47:1-20. [PMID: 31147158 DOI: 10.1016/j.cytogfr.2019.05.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Kurita K, Ishikawa K, Takeda K, Fujimoto M, Ono H, Kumagai J, Inoue H, Yokoh H, Yokote K. CXCL12-CXCR4 pathway activates brown adipocytes and induces insulin resistance in CXCR4-deficient mice under high-fat diet. Sci Rep 2019;9:6165. [PMID: 30992469 DOI: 10.1038/s41598-019-42127-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
48 Yoon JE, Kim Y, Kwon S, Kim M, Kim YH, Kim JH, Park TJ, Kang HY. Senescent fibroblasts drive ageing pigmentation: ​A potential therapeutic target for senile lentigo. Theranostics 2018;8:4620-32. [PMID: 30279727 DOI: 10.7150/thno.26975] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 12.3] [Reference Citation Analysis]
49 Shima K, Kimura K, Ishida M, Kishikawa A, Ogawa S, Qi J, Shen WR, Ohori F, Noguchi T, Marahleh A, Kitaura H. C-X-C Motif Chemokine 12 Enhances Lipopolysaccharide-Induced Osteoclastogenesis and Bone Resorption In Vivo. Calcif Tissue Int 2018;103:431-42. [PMID: 29845409 DOI: 10.1007/s00223-018-0435-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]